Pediatrics, Princess Nora bint Abdulrahman University, King Abdullah bin Abdulaziz University Hospital, Riyadh, Al Riyadh, Saudi Arabia.
Pediatrics, McMaster University, Hamilton, Ontario, Canada.
Arch Dis Child Fetal Neonatal Ed. 2020 Mar;105(2):164-171. doi: 10.1136/archdischild-2019-316832. Epub 2019 Jun 27.
Lung ultrasonography (LUS) is increasingly used to identify various neonatal respiratory disorders. There is emerging evidence that it can identify infants with significant lung disease who need surfactant treatment or mechanical ventilation.
To systematically review the accuracy of LUS in determining the need for surfactant treatment or mechanical ventilation in infants with respiratory distress treated with nasal continuous positive airway pressure (NCPAP).
Database search include EMBASE, Medline, CINAHL and Cochrane central from inception until 17 October 2018. Included is diagnostic accuracy studies reporting LUS evaluating surfactant therapy/mechanical ventilation. Two authors extracted data independently and assessed quality. Quality Assessment of Diagnostic Accuracy Studies-2 tool was used to determine the methodological quality.
Six studies involving 485 infants included in the review. Three studies used LUS score, two used type 1 lung profile, and one used high-risk LUS to evaluate the outcome. The pooled sensitivity and specificity at LUS score cut-off >5-6 was 88% (95% CI 80% to 93%) and 82% (95% CI 74% to 89%), respectively. Infants with LUS score >5-6 were at significantly increased risk of surfactant treatment compared with infants with LUS score <5-6 (relative risk=7.51; 95% CI 4.16 to 13.58; two studies; participants=189; I=0%). The diagnostic accuracy of type 1 lung profile was better in younger preterm infants (sensitivity 88.9%, specificity 100%) compared with late preterm and term infants (sensitivity 100%, specificity 28%).
LUS, particularly LUS score, can be used accurately to determine the need for surfactant replacement treatment or mechanical ventilation in infants with respiratory distress treated with NCPAP support. The accuracy is better in younger preterm infants compared with late preterm and term infants.
CRD42018115135.
超声在肺(LUS)越来越多地用于识别各种新生儿呼吸疾病。有新的证据表明,它可以识别出需要表面活性剂治疗或机械通气的患有严重肺部疾病的婴儿。
系统地回顾 LUS 在确定需要接受表面活性剂治疗或机械通气的接受鼻持续气道正压通气(NCPAP)治疗的呼吸窘迫婴儿中的准确性。
数据库搜索包括从开始到 2018 年 10 月 17 日的 EMBASE、Medline、CINAHL 和 Cochrane Central。包括报告评估表面活性剂治疗/机械通气的 LUS 的诊断准确性研究。两位作者独立提取数据并评估质量。使用诊断准确性研究质量评估-2 工具来确定方法学质量。
综述中纳入了 6 项涉及 485 名婴儿的研究。3 项研究使用 LUS 评分,2 项研究使用 1 型肺谱,1 项研究使用高危 LUS 来评估结果。LUS 评分截断值>5-6 时的汇总敏感性和特异性分别为 88%(95%CI 80%至 93%)和 82%(95%CI 74%至 89%)。与 LUS 评分<5-6 的婴儿相比,LUS 评分>5-6 的婴儿接受表面活性剂治疗的风险显著增加(相对风险=7.51;95%CI 4.16 至 13.58;两项研究;参与者=189;I=0%)。1 型肺谱的诊断准确性在早产儿中较好(敏感性 88.9%,特异性 100%),而在晚期早产儿和足月婴儿中较差(敏感性 100%,特异性 28%)。
LUS,特别是 LUS 评分,可以准确地用于确定接受 NCPAP 支持治疗的呼吸窘迫婴儿是否需要接受表面活性剂替代治疗或机械通气。在早产儿中,其准确性优于晚期早产儿和足月婴儿。
PROSPERO 注册号:CRD42018115135。